230 related articles for article (PubMed ID: 28785100)
21. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
22. Anti-JAM-C therapy eliminates tumor engraftment in a xenograft model of mantle cell lymphoma.
Doñate C; Vijaya Kumar A; Imhof BA; Matthes T
J Leukoc Biol; 2016 Nov; 100(5):843-853. PubMed ID: 27256571
[TBL] [Abstract][Full Text] [Related]
23. Periostin Mediates TGF-β-Induced Epithelial Mesenchymal Transition in Prostate Cancer Cells.
Hu Q; Tong S; Zhao X; Ding W; Gou Y; Xu K; Sun C; Xia G
Cell Physiol Biochem; 2015; 36(2):799-809. PubMed ID: 26021267
[TBL] [Abstract][Full Text] [Related]
24. β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway.
Hu T; Gao Y
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32010942
[TBL] [Abstract][Full Text] [Related]
25. Junctional adhesion molecule-A is down-regulated in anaplastic thyroid carcinomas and reduces cancer cell aggressiveness by modulating p53 and GSK3 α/β pathways.
Orlandella FM; Mariniello RM; Iervolino PLC; Auletta L; De Stefano AE; Ugolini C; Greco A; Mirabelli P; Pane K; Franzese M; Denaro M; Basolo F; Salvatore G
Mol Carcinog; 2019 Jul; 58(7):1181-1193. PubMed ID: 30834573
[TBL] [Abstract][Full Text] [Related]
26. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Hagner PR; Man HW; Fontanillo C; Wang M; Couto S; Breider M; Bjorklund C; Havens CG; Lu G; Rychak E; Raymon H; Narla RK; Barnes L; Khambatta G; Chiu H; Kosek J; Kang J; Amantangelo MD; Waldman M; Lopez-Girona A; Cai T; Pourdehnad M; Trotter M; Daniel TO; Schafer PH; Klippel A; Thakurta A; Chopra R; Gandhi AK
Blood; 2015 Aug; 126(6):779-89. PubMed ID: 26002965
[TBL] [Abstract][Full Text] [Related]
27. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
[TBL] [Abstract][Full Text] [Related]
28. Junctional adhesion molecule-A promotes proliferation and inhibits apoptosis of gastric cancer.
Ikeo K; Oshima T; Shan J; Matsui H; Tomita T; Fukui H; Watari J; Miwa H
Hepatogastroenterology; 2015; 62(138):540-5. PubMed ID: 25916097
[TBL] [Abstract][Full Text] [Related]
29. The tumor suppressive role of inhibin βA in diffuse large B-cell lymphoma.
Jiang L; Si T; Yu M; Zeng X; Morse HC; Lu Y; Ouyang G; Zhou JX
Leuk Lymphoma; 2018 May; 59(5):1202-1212. PubMed ID: 28877610
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells.
Sun R; Zhang PP; Weng XQ; Gao XD; Huang CX; Wang L; Hu XX; Xu PP; Cheng L; Jiang L; Fu D; Qu B; Zhao Y; Feng Y; Dou HJ; Zheng Z; Zhao WL
Signal Transduct Target Ther; 2022 Mar; 7(1):80. PubMed ID: 35301282
[TBL] [Abstract][Full Text] [Related]
31. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.
Wang J; Xu-Monette ZY; Jabbar KJ; Shen Q; Manyam GC; Tzankov A; Visco C; Wang J; Montes-Moreno S; Dybkær K; Tam W; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Ferreri AJM; Wang S; Møller MB; Piris MA; Medeiros LJ; Li Y; Pham LV; Young KH
Am J Pathol; 2017 Aug; 187(8):1700-1716. PubMed ID: 28627414
[TBL] [Abstract][Full Text] [Related]
32. AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation.
Tsai HJ; Shih NY; Kuo SH; Cheng AL; Lin HY; Chen TY; Chang KC; Lin SF; Chang JS; Chen LT
Leuk Lymphoma; 2015; 56(9):2674-82. PubMed ID: 25535814
[TBL] [Abstract][Full Text] [Related]
33. The F11 Receptor (F11R)/Junctional Adhesion Molecule-A (JAM-A) (F11R/JAM-A) in cancer progression.
Czubak-Prowizor K; Babinska A; Swiatkowska M
Mol Cell Biochem; 2022 Jan; 477(1):79-98. PubMed ID: 34533648
[TBL] [Abstract][Full Text] [Related]
34. Functional inhibition of F11 receptor (F11R/junctional adhesion molecule-A/JAM-A) activity by a F11R-derived peptide in breast cancer and its microenvironment.
Bednarek R; Selmi A; Wojkowska D; Karolczak K; Popielarski M; Stasiak M; Salifu MO; Babinska A; Swiatkowska M
Breast Cancer Res Treat; 2020 Jan; 179(2):325-335. PubMed ID: 31650345
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
Zhao C; Huang R; Zeng Z; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Yan P; Huang Z; Shi J
Aging (Albany NY); 2021 May; 13(10):14131-14158. PubMed ID: 34001679
[TBL] [Abstract][Full Text] [Related]
36. Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.
Lu L; Zhu F; Zhang M; Li Y; Drennan AC; Kimpara S; Rumball I; Selzer C; Cameron H; Kellicut A; Kelm A; Wang F; Waldmann TA; Rui L
Proc Natl Acad Sci U S A; 2018 Jan; 115(3):E498-E505. PubMed ID: 29295936
[TBL] [Abstract][Full Text] [Related]
37. Abrogation of junctional adhesion molecule-A expression induces cell apoptosis and reduces breast cancer progression.
Murakami M; Giampietro C; Giannotta M; Corada M; Torselli I; Orsenigo F; Cocito A; d'Ario G; Mazzarol G; Confalonieri S; Di Fiore PP; Dejana E
PLoS One; 2011; 6(6):e21242. PubMed ID: 21695058
[TBL] [Abstract][Full Text] [Related]
38. Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition.
Shi X; Lan X; Chen X; Zhao C; Li X; Liu S; Huang H; Liu N; Zang D; Liao Y; Zhang P; Wang X; Liu J
Sci Rep; 2015 Apr; 5():9694. PubMed ID: 25853502
[TBL] [Abstract][Full Text] [Related]
39. Vernodalol enhances TRAIL-induced apoptosis in diffuse large B-cell lymphoma cells.
Wu W; Yang Y; Deng G; Ma L; Wei G; Zheng G; Han X; He D; Zhao Y; He J; Cai Z; Yu R
Mol Carcinog; 2017 Oct; 56(10):2190-2199. PubMed ID: 28467689
[TBL] [Abstract][Full Text] [Related]
40. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
Wang C; Li W; Liu C; He H; Bai O
Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
